menu
    • menu
    [{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"5","companyTruncated":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Frontage Laboratories, Inc \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Frontage Laboratories, Inc \/ Eisai"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Diosmin","moa":"Aryl hydrocarbon receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc"},{"orgOrder":0,"company":"Tigermed","sponsor":"Shanghai Zhimeng Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ZM-H1505R","moa":"Hepatitis B virus Capsid protein (HBV C)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"11","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Zhejiang Hisun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Undisclosed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Zhuhai Trinomab Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TNM002","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Multitude Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AMT-151","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"HighField Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HF1K16","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Immorna","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"JCXH-105","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"8","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Immorna","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"JCXH-108","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ITALY","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Pediafl\u00f9","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ITALY","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Sonidor","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TL-001","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VG290131","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"}]

    Find Clinical Drug Pipeline Developments & Deals by Tigermed

    Menu

    Tigermed

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Frontage Laboratories, Inc

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Frontage Laboratories, Inc

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPC-15

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Recipient : Silo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Silo Pharma Starts Key Safety Study for PTSD Drug SPC-15 at Frontage Labs

                            Details : The agreement aims for a FDA requested 7-day safety and toxicology large animal study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 14, 2025

                            Lead Product(s) : SPC-15

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Recipient : Silo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TL-001

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : TrueLab Biopharmaceutical Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety and Pharmacokinetics Study of TL-001 in Healthy Adults

                            Details : TL-001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : TL-001

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : TrueLab Biopharmaceutical Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anakinra

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase IV

                            Recipient : Swedish Orphan Biovitrum AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF

                            Details : Anakinra is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Familial Mediterranean Fever.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 30, 2024

                            Lead Product(s) : Anakinra

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase IV

                            Recipient : Swedish Orphan Biovitrum AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JCXH-105

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Immorna

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

                            Details : JCXH-105 is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Herpes Zoster.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 03, 2024

                            Lead Product(s) : JCXH-105

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Immorna

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JCXH-108

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Immorna

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

                            Details : JCXH-108 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Communicable Diseases.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 21, 2024

                            Lead Product(s) : JCXH-108

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Immorna

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Frontage Laboratories, Inc

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Frontage Laboratories, Inc

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : Mira Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mira Pharmaceuticals Reports Preclinical Results for Ketamir-2, Aiming for IND Submission

                            Details : Ketamir-2, a novel oral ketamine analog, is being evaluated for its potential ultra-rapid antidepressant effects in major depressive disorder with suicidal ideation and treatment-resistant depression.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            April 02, 2024

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : Mira Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VG290131

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Zhejiang Vimgreen Pharmaceuticals, Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Study of Single and Multiple Doses of VG290131 in Healthy Subjects

                            Details : VG290131 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 13, 2023

                            Lead Product(s) : VG290131

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Zhejiang Vimgreen Pharmaceuticals, Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difelikefalin Acetate

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus

                            Details : Difelikefalin is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pruritus.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 02, 2023

                            Lead Product(s) : Difelikefalin Acetate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difelikefalin Acetate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Recipient : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis

                            Details : Difelikefalin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Failure, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 02, 2023

                            Lead Product(s) : Difelikefalin Acetate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Recipient : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed

                            Tigermed

                            China arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diosmin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Recipient : Giellepi S.p.A

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Randomised, Double-blind, Placebo-controlled to Assess the Efficacy and Safety of the Food Supplement Microsmi...

                            Details : Diosmin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Haemorrhoids.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 01, 2023

                            Lead Product(s) : Diosmin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Recipient : Giellepi S.p.A

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth